poly(rC) binding protein 3Genealiases: ALPHA-CP3 · PCBP3-OT1 · PCBP3OT
Q-omics provides the consensus-scored PCBP3 profile across patient tissues and cancer cell-line models. PCBP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PCBP3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, PCBP3 protein abundance shows 15,323 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where PCBP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCBP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCBP3 survival associations across molecular data types. PCBP3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCBP3 RNA expression–survival associations across cancer types. High PCBP3 expression shows unfavorable associations in KIRC and COAD, but favorable associations in UVM, LGG, ACC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PCBP3 RNA expression.
This table summarizes PCBP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCBP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCBP3 shows lower tumor expression in KIRC, UCEC, BRCA and KICH and higher tumor expression in HNSC and LUAD. The KIRC box plot shows higher PCBP3 RNA expression in normal versus tumor tissue (log2 FC = −0.911, t-test p < 0.001).
This table shows molecular features associated with PCBP3 in patient tissues and cancer cell lines. In patient samples, PCBP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCBP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
